Bull Case

ResMed sustains double-digit device and mask demand as sleep-apnea diagnosis and treatment adoption expand, lifting revenue growth above direct peers like Philips and Fisher & Paykel Healthcare.

Higher recurring mask and consumables mix, supported by installed-base replacement cycles, preserves gross margin and keeps operating leverage ahead of most respiratory-device peers.

Cloud-connected software and digital adherence tools improve patient retention and provider workflow integration, reducing churn and supporting premium pricing versus less-connected competitors.

Net cash balance and strong interest coverage allow continued share repurchases and selective investment, limiting financing drag relative to more leveraged medtech peers.

Base Case

ResMed maintains mid-to-high single-digit revenue growth as sleep-disordered breathing demand remains healthy, with growth outpacing slower-moving legacy respiratory peers.

Stable mask replacement demand and a favorable mix toward recurring consumables support operating margins near current levels, despite normal pricing pressure from competitors.

Connected-device adoption and software penetration continue to deepen, but benefits are incremental rather than transformative versus other large sleep-care platforms.

Strong balance-sheet flexibility and disciplined capital allocation preserve earnings resilience, keeping downside limited relative to peers with higher leverage or weaker cash generation.

Bear Case

Competitive pricing pressure or reimbursement friction slows device and mask growth, narrowing ResMed’s revenue premium versus Philips and other sleep-therapy peers.

A weaker replacement cycle or lower patient adherence reduces consumables pull-through, compressing margins because recurring mix no longer offsets input and freight costs.

If channel inventory normalizes slowly or demand softens in key geographies, operating leverage fades and earnings growth trails the broader medtech peer set.

Even with a strong balance sheet, slower top-line momentum would limit capital-return support and leave valuation more exposed to multiple compression.

Overall Score

ResMed’s forward profile remains structurally strong versus peers, with recurring demand, margin resilience, and balance-sheet strength outweighing plausible downside scenarios.